CD274 and cancer: Lastly, 3M-052 (a lipid-modified imidazoquinoline derivative), was assessed as a cancer vaccine adjuvant demonstrating marked synergistic efficacy in tandem with checkpoint-blocking antibodies for CTLA4 and PDL-1 (190).